雷帕霉素可预防小鼠胸主动脉瘤及夹层形成
本研究将3周龄C57BL/6J雄性小鼠随机分为对照组(n=6)、BAPN组(Gp A;n=15)、BAPN联合雷帕霉素5 mg组(Gp B;n=8)和BAPN联合雷帕霉素10 mg组(Gp C;n=8),BAPN灌胃4周,Gp B和Gp C在BAPN给药1周后经灌胃给予雷帕霉素21天。结果显示雷帕霉素可抑制TAAD形成,并降低胸主动脉直径、减轻弹性纤维断裂及炎症细胞浸润。
要点
- BAPN处理诱导小鼠TAAD形成,对照组、Gp A、Gp B、Gp C的TAAD发生率分别为0%、80%、25%、37.5%。
- Gp B和Gp C的升主动脉及主动脉弓直径均小于Gp A(P < .05)。
- 雷帕霉素可能通过抑制mTOR信号及减少炎症细胞浸润和MMP9产生来抑制TAAD形成。
核心结论
- 雷帕霉素抑制了TAAD形成,可能通过抑制mTOR信号通路、减少炎症细胞浸润及基质金属蛋白酶9产生实现。
- 作者认为,使用雷帕霉素靶向mTOR信号通路可能成为TAAD临床治疗的一种有利调控方式。
研究设计与样本
- 研究为小鼠实验,将3周龄C57BL/6J雄性小鼠随机分为对照组(n=6)、BAPN组(Gp A;n=15)、BAPN联合雷帕霉素5 mg组(Gp B;n=8)和BAPN联合雷帕霉素10 mg组(Gp C;n=8)。
- Gp A、Gp B、Gp C给予BAPN(1 g/kg/d)4周;BAPN给药1周后,Gp B和Gp C经灌胃给予雷帕霉素(5 mg/kg/d或10 mg/kg/d)21天。
- 第14天取材胸主动脉行Western blot和免疫荧光染色,第28天行形态学和组织学分析。
主要发现
- BAPN处理诱导小鼠TAAD形成,对照组、Gp A、Gp B、Gp C的TAAD发生率分别为0%、80%、25%、37.5%。
- Gp B vs Gp A:离体升主动脉直径1.07 ± 0.21 mm vs 1.80 ± 0.67 mm(P < .05),离体主动脉弓直径1.51 ± 0.40 mm vs 2.70 ± 1.06 mm(P < .05)。
- Gp C vs Gp A:离体升主动脉直径1.10 ± 0.33 mm vs 1.80 ± 0.67 mm(P < .05),离体主动脉弓直径1.55 ± 0.56 mm vs 2.70 ± 1.06 mm(P < .05)。
- TAAD小鼠主动脉表现为弹性纤维断裂、大量炎症细胞浸润及基质金属蛋白酶产生显著增加,雷帕霉素治疗减轻了这些改变。
- TAAD主动脉组织中p-S6K和p-S6蛋白水平显著升高,雷帕霉素抑制了其升高。
临床怎么用
- 作者认为,使用雷帕霉素靶向mTOR信号通路可能成为TAAD临床治疗的一种有利调控方式。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The purpose of this study was to investigate whether rapamycin inhibits the development of thoracic aortic aneurysm and dissection (TAAD) in mice. METHODS: Three-week-old C57BL/6J male mice were fed a normal diet and randomized into a control group (n = 6), β-aminopropionitrile fumarate (BAPN) group (Gp A; n = 15), BAPN plus rapamycin (5 mg) group (Gp B; n = 8), and BAPN plus rapamycin (10 mg) group (Gp C; n = 8). Gp A, Gp B, and Gp C were administered BAPN (1 g/kg/d) for 4 weeks. One week after BAPN administration, Gp B and Gp C were treated with rapamycin (5 mg/kg/d or 10 mg/kg/d) through gavage for 21 days. Thoracic aortas were harvested for Western blot and immunofluorescence staining at day 14 and for morphologic and histologic analyses at day 28. RESULTS: BAPN treatment induced TAAD formation in mice. The incidence of TAAD in control, Gp A, Gp B, and Gp C mice was 0%, 80%, 25%, and 37.5%, respectively. Smaller thoracic aortic diameters (ascending aorta and arch) were observed in Gp B and Gp C mice than in Gp A mice (Gp B vs Gp A: ascending aorta, ex vivo, 1.07 ± 0.21 mm vs 1.80 ± 0.67 mm [P < .05]; aortic arch, ex vivo, 1.51 ± 0.40 mm vs 2.70 ± 1.06 mm [P < .05]; Gp C vs Gp A: ascending aortas, ex vivo, 1.10 ± 0.33 mm vs 1.80 ± 0.67 mm [P < .05]; aortic arch, ex vivo, 1.55 ± 0.56 mm vs 2.70 ± 1.06 mm [P < .05]). TAAD mice exhibited elastin fragmentation, abundant inflammatory cell infiltration, and significantly increased matrix metalloproteinase production in the aorta, and rapamycin treatment alleviated these changes. The protein levels of p-S6K and p-S6 in TAAD aortic tissues increased significantly, whereas they were suppressed by rapamycin. CONCLUSIONS: Rapamycin suppressed TAAD formation, probably by inhibition of mechanistic target of rapamycin signaling and reduction of inflammatory cell infiltration and matrix metalloproteinase 9 production. Targeting of the mechanistic target of rapamycin signaling pathway using rapamycin may be a favorable modulation for the clinical treatment of TAAD.
引用
- Zhou B, Li W, Zhao G, et al. Rapamycin prevents thoracic aortic aneurysm and dissection in mice. J Vasc Surg. 2018. PMID: 30253896. doi:10.1016/j.jvs.2018.05.246
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。